Close Menu

Sponsors

Researchers are continuing to collect data on economic, racial, and other factors that could be addressed to make precision medicine access more equitable.

Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.

Carebox's system matches eligibility criteria from clinical trial databases with patients' health and genomic data to identify potentially relevant studies.

The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.

An Invitae-led retrospective study found almost a third of cancer patients who underwent germline genetic testing after tumor sequencing had pathogenic variants.